Pfizer China and Xianwei Da Biologicals reach a partnership to accelerate the commercialization process of biased GLP-1

2026-02-28 05:14:12

Abstract generation in progress

On February 24, Pfizer China and Hangzhou Xianweida Biological (hereinafter referred to as Xianweida Biological) announced that the two parties have reached a strategic partnership for the commercialization of the next-generation biased GLP-1 receptor agonist Ecnoglutide injection (English: Ecnoglutide injection, hereinafter referred to as Ecnoglutide). According to the agreement, Pfizer will obtain exclusive commercialization rights for this product in mainland China, marking its first step in the strategic layout of the global metabolic field in China; at the same time, Xianweida Biological will serve as the marketing authorization holder (MAH) for the licensed product, responsible for the research and development, registration, production, and supply of the licensed product.

Xianweida Biological will be entitled to receive a total payment from Pfizer of up to $495 million, including upfront payments, registration, and sales milestone payments. Ecnoglutide is a new generation cAMP-biased GLP-1 receptor agonist independently developed by Xianweida Biological, providing more precise treatment options for patients with type 2 diabetes and long-term weight management.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes